![]() | |
Clinical data | |
---|---|
Trade names | Zepsun |
Other names | CM-4307 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C21H16ClF3N4O3 |
Molar mass | 464.83 g·mol−1 |
3D model ( JSmol) | |
| |
|
Donafenib, sold under the brand name Zepsun, is a pharmaceutical drug for the treatment of cancer.
In China, donafenib is approved for the treatment of unresectable hepatocellular carcinoma in patients who have not previously received systemic treatment. [1] [2]
Donafenib is a kinase inhibitor that targets Raf kinase and various receptor tyrosine kinases. [3] It is a deuterated derivative of sorafenib with improved pharmacokinetic properties. [4] [5]
![]() | |
Clinical data | |
---|---|
Trade names | Zepsun |
Other names | CM-4307 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C21H16ClF3N4O3 |
Molar mass | 464.83 g·mol−1 |
3D model ( JSmol) | |
| |
|
Donafenib, sold under the brand name Zepsun, is a pharmaceutical drug for the treatment of cancer.
In China, donafenib is approved for the treatment of unresectable hepatocellular carcinoma in patients who have not previously received systemic treatment. [1] [2]
Donafenib is a kinase inhibitor that targets Raf kinase and various receptor tyrosine kinases. [3] It is a deuterated derivative of sorafenib with improved pharmacokinetic properties. [4] [5]